Drug-drug osteonecrosis of the jaw as a rare complication of bone metastases treatment in cancer patients
https://doi.org/10.52485/19986173_2023_4_125
Abstract
Drug-induced osteonecrosis of the jaw (DONJ) is a rare complication of antiresorptive therapy, which in oncology is used in the treatment of bone metastases to prevent the occurrence and treatment of adverse bone events (pain syndrome, pathological fractures, compression syndrome). The article presents a clinical case of the occurrence of DOC in a patient with progression of kidney cancer with the presence of bone metastases, who received long-term targeted therapy in combination with Denosumab (an antibody that inhibits bone tissue resorption). A review of the literature on the incidence, risk factors and treatment methods of LONJ is provided. The need to carefully collect anamnesis, including oncological history, the presence of a connection with the use of antiresorptive drugs, and identification of clinical and instrumental signs of LOC will allow a diagnosis to be made. It is necessary to remember the possibility of the occurrence of LOC in cancer patients receiving antiresorptive therapy, both oncologists and dentists, general practitioners in order to prevent the development of LOC, timely diagnosis and treatment, taking into account the possibility of a fatal outcome due to the development of sepsis.
About the Authors
E. V. Kajukova
Chita State Medical Academy
Russian Federation
Russian Federation
39а Gorky str., Chita, 672000
N. I. Troitskaya
Chita State Medical Academy
Russian Federation
Russian Federation
39а Gorky str., Chita, 672000
S. G. Batoeva
Chita State Medical Academy
Russian Federation
Russian Federation
39а Gorky str., Chita, 672000
References
1. Bagrova S.G., Kopp M.V., Kutukova S.I., Manzjuk L.V., Semiglazova T.Ju. The use of osteomodifying agents (oma) for the prevention and treatment of bone tissue pathology in malignant neoplasms. Zlokachestvennye opuholi. 2021. 10(3s2-2). 35-44. in Russian.
2. Bagrova S.G., Basin E.M., Valiev A.K. et al. Prevention and treatment of bone tissue pathology in malignant neoplasms. Zlokachestvennye opuholi: Prakticheskie rekomendacii RUSSCO. 2022. 12(3s2). 40–54. in Russian.
3. Spevak E.M., Cymbal A.N. Bisphosphonate osteonecrosis of the jaws: current state of the problem. Kazanskij medicinskij zhurnal. 2017. 98 (1). 91-95. in Russian.
4. Fomichev E.V., Kirpichnikov M.V., Jarygina E.N., Podol'skij V.V., Nesterov A.A. Bisphosphonate osteonecrosis of the jaws. Vestnik Volgogradskogo gosudarstvennogo medicinskogo universiteta. 2019. 1(69). 3-8. in Russian.
5. Minabudinova A.K., Homutova E.Ju. Radiation diagnostics of drug-induced osteonecrosis of the jaws. Sovremennye tehnologii: tendencii i perspektivy razvitija. 2022. 204-213. in Russian.
6. Yarom N., Shapiro C.L., Peterson D.E. et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ ASCO Clinical Practice Guideline. J. Clin Oncol. 2019. 37(25). 2270-2290. doi: 10.1200/JCO.19.01186.
7. Aleeva M.M., Urakova E.V., Leksin R.V. Bisphosphonate osteonecrosis of the jaws: risk factors and treatment features. Prakticheskaja medicina. 2017. 8(109). 13-17. in Russian.
8. Yoneda T., Hagino H., Sugimoto T., et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J. Bone Miner Metab. 2017. 35(1). 6–19. DOI: 10.1007/s00774-016-0810-7. in Russian.
9. Kulieva I.Je., Besova N.S. Experience with the use of zoledronic acid (Rezorba) for the treatment of patients with bone metastases. Jeffektivnaja farmakoterapija. 2012. 37-2. 24-31. in Russian.
10. Stenina M.B., Petrova A.D. Targeted approach in the treatment of pathology of the skeletal system. Opuholi zhenskoj reproduktivnoj sistemy. 2010. 4. 43-48. in Russian.
11. Lesnjak O.M. Osteonecrosis of the jaw on antiresorptive therapy for osteoporosis: prevention, diagnosis, patient management. Osteoporoz i osteopatii. 2023. 1(26). 4-12. in Russian.
12. Gorobec S.M., Romanenko I.G., Dzherelej A.A., Bobkova S.A., Krjuchkov D.Ju. et al. Dental aspects of adverse drug reactions. Tavricheskij mediko-biologicheskij vestnik. 2018. 21(3). 166-174. in Russian.
13. Chagaev M.V., Kaloeva A.M. Osteonecrosis of the jaws caused by taking antiresorptive drugs. Nauchnyj Lider. 2022. 16–20. in Russian.
14. Kawahara M., Kuroshima S., Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021. 7(1). 47. doi: https://doi.org/10.1186/s40729-021-00323-0.
15. Ruggiero S.L., Dodson T.B., Aghaloo T. et al. American Association of Oral and Maxillofacial Surgeons’Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022. 80(5). 920-943. doi: https://doi.org/10.1016/j.joms.2022.02.008.
16. Timofeev A.A., Ushko N.A., Ustimov A.V., Miroshnik A. A. Chemotherapy osteonecrosis. Collection of scientific works of Stomatology Institute, Shupyk NMAPE 2019. 7. 125–131. in Russian.
Review
For citations:
Kajukova E.V., Troitskaya N.I., Batoeva S.G. Drug-drug osteonecrosis of the jaw as a rare complication of bone metastases treatment in cancer patients. Transbaikalian Medical Bulletin. 2023;(4):125-131. (In Russ.) https://doi.org/10.52485/19986173_2023_4_125
Views:
180
Email this article 